Summit Therapeutics (SMMT) Other Operating Expenses (2017 - 2024)
Summit Therapeutics' (SMMT) quarterly Other Operating Expenses came in at $205000.0 in Q4 2024, up 14.53% YoY from $179000.0 in Q1 2024, and up 177.65% on a QoQ basis from -$264000.0 in Q3 2024.
Summit Therapeutics (SMMT) Other Operating Expenses (2017 - 2024) Analysis & Trends
Summit Therapeutics (SMMT) has 8 years of Other Operating Expenses data on file, last reported at $205000.0 in Q4 2024.
- Quarterly Other Operating Expenses rose 14.53% year-over-year to $205000.0 in Q4 2024, while the trailing twelve-month figure through Sep 2025 was $205000.0 (down 28.57% YoY) and the FY2024 annual result came in at $313000.0, down 68.73% from the prior year.
- Other Operating Expenses improved to $205000.0 in Q4 2024, from -$264000.0 in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of $6.8 million in Q1 2020 to a low of -$264000.0 in Q3 2024.
- A 5-year average of $2.8 million and a median of $3.4 million in 2020 frame the typical range for Other Operating Expenses.
- The widest YoY moves for Other Operating Expenses: up 688.89% in 2024, down 199.62% in 2024.
- Tracing SMMT's Other Operating Expenses over 5 years: stood at $4.4 million in 2020, then climbed by 5.18% to $4.6 million in 2021, then sank by 75.31% to $1.1 million in 2022, then sank by 84.2% to $179000.0 in 2023, then gained by 14.53% to $205000.0 in 2024.
- The last three Other Operating Expenses figures came in at $205000.0 (Q4 2024), -$264000.0 (Q3 2024), and $159000.0 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Summit Therapeutics | 10.59 Bn | 9.90 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 205,000.00 |
| Sep 30, 2024 | -264,000.00 |
| Jun 30, 2024 | 159,000.00 |
| Mar 31, 2024 | 213,000.00 |
| Dec 31, 2023 | 179,000.00 |
| Sep 30, 2023 | 265,000.00 |
| Jun 30, 2023 | -27,000.00 |
| Mar 31, 2023 | 584,000.00 |
| Dec 31, 2022 | 1.13 Mn |
| Sep 30, 2022 | 5.46 Mn |
| Jun 30, 2022 | 3.01 Mn |
| Mar 31, 2022 | 4.81 Mn |
| Dec 31, 2021 | 4.59 Mn |
| Sep 30, 2021 | 4.81 Mn |
| Jun 30, 2021 | 6.12 Mn |
| Mar 31, 2021 | 5.45 Mn |
| Dec 31, 2020 | 4.36 Mn |
| Sep 30, 2020 | 4.31 Mn |
| Jun 30, 2020 | 3.82 Mn |
| Mar 31, 2020 | 6.82 Mn |